CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted its supplementary market filing for the ACYW135 Meningococcal Conjugate Vaccine (CRM197), trade named Menhycia. The Chinese biotechnology company is looking to extend the vaccine’s approved age range to include children from 3 months to 6 years (83 months), up from the current range of 3 months to 3 years (47 months).
Menhycia’s Role in Preventing Meningitis
Menhycia was initially approved for marketing in China in December 2021, targeting the prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis infections in groups A, C, Y, and W135. This vaccine plays a critical role in public health by protecting against these potentially fatal infections.
Financial Performance of CanSino’s Meningococcal Vaccine Products
CanSino Biologics’ meningococcal vaccine products, including Menhycia, have shown significant financial growth, generating RMB 516 million (USD 71.28 million) during the first three quarters of 2024. This represents a 39.07% increase compared to the same period in the previous year, underscoring the strong market demand and the vaccine’s importance in disease prevention.-Fineline Info & Tech
